Corcept Therapeutics Inc

Research Corcept Therapeutics Inc (CORT) on Bullrun: valuation model: 81.4% overvalued, market cap USD 9.44B, P/E 251.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCORT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal81.4% overvalued
• Market capUSD 9.44B
• P/E251.1
• Financial periodFY2025
• RevenueUSD 761.41M
• Revenue growth12.8%
• Net incomeUSD 99.65M
• Free cash flowUSD 141.79M
• Gross margin98.3%

Valuation Snapshot

Bullrun's latest valuation model marks Corcept Therapeutics Inc as 81.4% overvalued; latest market cap is USD 9.44B; P/E is 251.1.

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Frequently asked questions

Is Corcept Therapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Corcept Therapeutics Inc as 81.4% overvalued.

What is Corcept Therapeutics Inc's market cap?

Corcept Therapeutics Inc's market capitalization is USD 9.44B.

What is Corcept Therapeutics Inc's P/E ratio?

Corcept Therapeutics Inc's price-to-earnings (P/E) ratio is 251.1.

What does Corcept Therapeutics Inc do?

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.